EP Patent

EP1660100B1 — Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents

Assigned to Gentium SRL · Expires 2008-07-02 · 18y expired

What this patent protects

Formulations with anti-tumour action containing defibrotide and at least another active ingredient as active agents.

USPTO Abstract

Formulations with anti-tumour action containing defibrotide and at least another active ingredient as active agents.

Drugs covered by this patent

defibrotide-sodium (DEFIBROTIDE SODIUM)

Patent Metadata

Patent number: EP1660100B1
Jurisdiction: EP
Classification: —
Expires: 2008-07-02
Drug substance claim: No
Drug product claim: No
Assignee: Gentium SRL
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.